This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
With the emergence of the omicron variant, the U.S. is considering tightening international travel guidelines. The CDC said it might reduce the window for foreign travelers to submit a negative COVID-19 test from three days prior to one day before allowing entry.
Jill and Carlo cover the latest on Omicron, another school shooting in America and more. Plus, bidding farewell to 'transitory' inflation, and the controversy surrounding 'Lovely Bones' author Alice Sebold.
Sarav Arunachalam, air pollution scientist at the University of North Carolina at Chapel Hill, joins Cheddar Climate, where he discusses what he needs to happen when it comes to EV production on a global level to help reduce the effects of climate change.
The United Nations Secretary-General said this year that his agency's warning about climate change was a 'code red for humanity.' So how will political pledges to lower emissions, increase green energy, and ramp up electric vehicle infrastructure play out, and can we reverse some climate damage next year? Vijay Vaitheeswaran, Global energy & climate innovation editor for The Economist, and host of 'To a Lesser Degree,' The Economist’s podcast on climate change, joins Cheddar Climate to discuss what we can look ahead to in 2022, including global policy shifts and investments from the private and public sectors, holding global leaders accountable, and more.
In recent years, extreme weather events like flooding and wildfires have become more frequent, and more severe - and scientists say global warming is to blame. Climate crises could leave people in need of help, and that's where Global Rescue steps in. The crisis response firm employs former Navy Seals and Army Rangers to rescue travelers from climate-related emergencies. Global Rescue CEO Dan Richards joins Cheddar Climate to discuss.
Jennifer Lotito, president and COO at the non-profit (RED), joined Cheddar to discuss the CODE (RED) campaign as the organization looks to expand its mission to support both AIDS and COVID-19 relief. She explained that people can get involved in the campaign for Giving Tuesday and ahead of World AIDS Day by shopping (RED) branded products and even using credit card rewards points to add their own support. Lotito also pointed out that COVID-19 has also impacted HIV testing as people avoid clinics out of fear of the other pandemic.
NASA indefinitely delayed a spacewalk to repair an ISS antenna, citing concerns about space debris. It was unclear if the warning from the space agency to astronauts aboard the ISS was related to the recent destruction of a non-functioning Russian satellite.
